Iovance Biotherapeutics reports a gross margin of 53.2%, an operating margin of -60.8%, an EBITDA margin of -46.9%, and a net margin of -58.2%, but its operating margin is negative at -60.8%, its EBITDA margin is negative at -46.9%, and its net margin is negative at -58.2%. All available margins expanded year over year, led by operating margin with an increase of 105.5 percentage points.
Over the last 3 years, Iovance Biotherapeutics's margins averaged 0.74% gross, -5,529.81% operating, -4,950.85% EBITDA, and -5,324.9% net. All four current margins are above their three-year averages.
Gross margin expanded by 20.2 percentage points, operating margin by 105.5 percentage points, EBITDA margin by 91.5 percentage points, and net margin by 100.6 percentage points, led by operating margin with an increase of 105.5 percentage points.
Throughout the last 3 years, Iovance Biotherapeutics had an average gross margin of 0.74%. Against its three-year average, Iovance Biotherapeutics's gross margin is currently 53.2%, 52.5 percentage points above its three-year average. Looking back over the last 3 years, Iovance Biotherapeutics's gross margin reached 53.2% at its highest point in Sep 2026 and -335.6% at its lowest in Mar 2024.
Over the last 3 years, Iovance Biotherapeutics's operating margin averaged -5,529.81%. As of the latest period, Iovance Biotherapeutics's current operating margin is -60.8%, which is 5,469 percentage points above its three-year average. During this period, operating margin reached a high of -60.8% in Sep 2026 and a low of -38,735% in Dec 2023.
Iovance Biotherapeutics recorded an average EBITDA margin of -4,950.85% across the last 3 years. Iovance Biotherapeutics's current EBITDA margin is -46.9% and is 4,904 percentage points above its three-year average. The highest EBITDA margin for Iovance Biotherapeutics was -46.9% in Sep 2026, while the lowest was -34,851.9% in Dec 2023.
Reviewing the last 3 years, Iovance Biotherapeutics recorded an average net margin of -5,324.9%. Iovance Biotherapeutics's current net margin is -58.2% and is 5,266.7 percentage points above its three-year average. The highest net margin for Iovance Biotherapeutics was -58.2% in Sep 2026, while the lowest was -37,345.4% in Dec 2023.
Iovance Biotherapeutics's gross margin of 53.2% is lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 68.6%, Iovance Biotherapeutics's gross margin is 22% lower.
For the period ending Sep 30, 2026, IOVA recorded a gross margin of 53.2%.
For the period ending Sep 30, 2026, IOVA recorded an operating margin of -60.8%.
As of Sep 30, 2026, IOVA has an EBITDA margin of -46.9%.
As of Sep 30, 2026, IOVA has a negative net margin of -58.2%.
Iovance Biotherapeutics's gross, operating, EBITDA, and net margins averaged 0.7% gross, -5,529.8% operating, -4,950.9% EBITDA, and -5,324.9% net over the last 3 years.
Over this 5-year history, IOVA peaked at 53.2% gross in Sep 2026, -60.8% operating in Sep 2026, -46.9% EBITDA in Sep 2026, and -58.2% net in Sep 2026.
Looking back across 5 years, IOVA reached its lowest margins at -803.8% gross in Sep 2023, -179,988.7% operating in Jun 2023, -165,909.7% EBITDA in Jun 2023, and -175,981.1% net in Jun 2023.